BIOMARKERS FOR COMBINATION THERAPY FOR ER+ BREAST CANCER
Embodiments of the disclosure concern methods and compositions that facilitate determination of a suitable therapy for an individual in need thereof. In specific embodiments, the individual has ER+ breast cancer of a specific subtype that renders them suitable for a particular therapy and/or renders them unsuitable for a particular therapy. In specific cases, gene expression analysis determines that an individual is of Luminal B subtype and the individual is suited for combination therapy of one or more aromatase inhibitors and one or more selective estrogen receptor degraders (SERDs) and/or is not suitable for chemotherapy..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 14. Sept. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
ELLIS MATTHEW J [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-09-14, Last update posted on www.tib.eu: 2023-09-28, Last updated: 2023-09-29 |
|---|
| Patentnummer: |
WO2023172891 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA001790862 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA001790862 | ||
| 003 | DE-627 | ||
| 005 | 20240327213524.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240327s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA001790862 | ||
| 035 | |a (EPA)WO2023172891 | ||
| 035 | |a (EPA)87935904 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a ELLIS MATTHEW J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a BIOMARKERS FOR COMBINATION THERAPY FOR ER+ BREAST CANCER |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-09-14, Last update posted on www.tib.eu: 2023-09-28, Last updated: 2023-09-29 | ||
| 520 | |a Embodiments of the disclosure concern methods and compositions that facilitate determination of a suitable therapy for an individual in need thereof. In specific embodiments, the individual has ER+ breast cancer of a specific subtype that renders them suitable for a particular therapy and/or renders them unsuitable for a particular therapy. In specific cases, gene expression analysis determines that an individual is of Luminal B subtype and the individual is suited for combination therapy of one or more aromatase inhibitors and one or more selective estrogen receptor degraders (SERDs) and/or is not suitable for chemotherapy. | ||
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a ANURAG MEENAKSHI |4 aut | |
| 700 | 0 | |a PEROU CHARLES M |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 14. Sept. |
| 773 | 1 | 8 | |g year:2023 |g day:14 |g month:09 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/87935904/publication/WO2023172891A1?q=WO2023172891 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 14 |c 09 | ||